Key facts
- This page summarizes Aaron G.l. Fletcher's Form 4 filing for TFF Pharmaceuticals, Inc..
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 30 Dec 2022, 15:52.
Aaron G.l. Fletcher - 29 Dec 2022 Form 4 Insider Report for TFF Pharmaceuticals, Inc.
- Reporting relationship
- Director
- Issuer ticker
- N/A
- Reported as of
- 29 Dec 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 30 Dec 2022, 15:52:08 UTC
- Prior SEC filing
- 13 Dec 2022
- Next SEC filing
- 05 Jan 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Aaron G.L. Fletcher by Kirk Allen Coleman, as Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Aaron G.l. Fletcher filed Form 4 for TFF Pharmaceuticals, Inc. on 30 Dec 2022.
Change
- Previous filing in this sequence was filed on 13 Dec 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
TFFP
transaction
Derivative
Stock Options (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +33,475
- Change %
- Price
- $0.000000
- Shares after
- 33,475
- Date
- 29 Dec 2022
- Ownership
- To BP Directors for the benefit of Reporting Person
- Underlying class
- Common Stock
- Underlying amount
- 33,475
- Exercise price
- $0.8500
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
The options represent the annual option grant to non-executive members of the Board of Directors.